<PAGE> 1
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT PURSUANT
TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of Earliest Event Reported) FEBRUARY 9, 1996
------------------------
MEDSTONE INTERNATIONAL, INC.
- -------------------------------------------------------------------------------
(Exact Name of Issuer as Specified in Charter)
DELAWARE
- -------------------------------------------------------------------------------
(State or Other Jurisdiction of Incorporation)
0-16752 66-0439440
- --------------------------------- -----------------------------------------
(Commission File Number) (I.R.S. Employer Identification No.)
100 COLUMBIA, SUITE 100, ALISO VIEJO, CA 92656
- -------------------------------------------------------------------------------
(Address of Principal Executive Offices)
(714) 448-7700
- -------------------------------------------------------------------------------
(Registrants's Telephone Number, Including Area Code)
- -------------------------------------------------------------------------------
(Former Name or Former Address, if Changed Since Last Report)
<PAGE> 2
ITEM 2. ACQUISITION OR DISPOSITION OF ASSETS.
On February 9, 1996, the Company completed distribution to its
shareholders, as a dividend, 5,516,528 shares of the outstanding common stock
of each of the Endocare and UroGen subsidiaries. The Company will retain
ownership of 100,000 shares of each. Endocare received the accounts
receivable, inventory, prepaid expenses and fixed assets associated with the
endourology operations. Along with these assets, the Endocare division
received a $500,000 capital contribution. UroGen received the net fixed assets
of the biology operations, and a $500,000 capital contribution.
ITEM 7(B). PROFORMA FINANCIAL INFORMATION
All proforma financial information is incorporated by
reference from the proforma financial information included in the definitive
Form 10s filed for both Endocare and UroGen with the Securities and Exchange
Commission on February 9, 1996.
- 2 -
<PAGE> 3
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
MEDSTONE INTERNATIONAL, INC.
Dated: February 21, 1996
By: \s\ Mark Selawski
-------------------------------
Mark Selawski
Chief Financial Officer
- 3 -
